Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.

LF 15-0195, a novel immunosuppressive agent prevents rejection and induces operational tolerance in a mouse cardiac allograft model.

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Monotherapy with LF 15-0195, an Analogue of 15-Deoxyspergualin, Significantly Prolongs Renal Allograft Survival in Monkeys1

Synergistic Tolerance Induced by LF15-0195 and Anti-Cd45rb Monoclonal Antibody Through Suppressive Dendritic Cells1

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

Bioinspired Β-Glucan Microcapsules Deliver FK506 to Lymph Nodes for Treatment of Cardiac Allograft Acute Rejection

Selective CD28 Blockade by a Single-Chain Fv Inhibits T Cell Proliferation and Prevents Acute Rejection in a Murine Model of Cardiac Allotransplantion

Combined Use of Vitamin D-derived Drug and DBMC to Induce Tolerance on Heterotopic Rat Cardiac Allograft

Electrospun Polymer Fibers Modified with FK506 for the Long-Term Treatment of Acute Cardiac Allograft Rejection in a Heart Transplantation Model.

Lf15-0195 Generates Tolerogenic Dendritic Cells By Suppression Of Nf-Kappa B Signaling Through Inhibition Of Ikk Activity

Ursolic acid promotes robust tolerance to cardiac allografts in mice.

L6H21 Prolonged Rats Survival after Limb Allotransplantation by Inhibiting Acute Rejection.

Prevention of Acute and Chronic Rejection of Rat Heart Allografts by Oral Administration of Tolerogenic Donor Recipient Allochimeric Class I Mhc Proteins

Successful Tolerance Induction under CD40 Ligation in a Rodent Small Bowel Transplant Model: First Report of a Study with the Novel Antibody AH.F5.

Flt3l Combined with Rapamycin Promotes Cardiac Allograft Tolerance by Inducing Regulatory Dendritic Cells and Allograft Autophagy in Mice

Leflunomide Inhibits rat-to-Mouse Cardiac Xenograft Rejection by Suppressing Adaptive Immune Cell Response and NF-κB Signaling Activation

Comparative effects of hepatocyte growth factor and tacrolimus on acute liver allograft early tolerance

SYNERGISTIC TOLERANCE BY ADOPTIVE TRANSFER OF TOLEROGENIC DENDRITIC CELLS AND T REGULATORY CELLS:

Guiding Postablative Lymphocyte Reconstitution as a Route Toward Transplantation Tolerance

Selective Blockade of Il-15 by Soluble Il-15 Receptor Alpha-Chain Enhances Cardiac Allograft Survival